Table 6.
Eligibility criteria for review on functional imaging modality.
| Study characteristic | Inclusion criteria | Exclusion criteria |
| Patient population | Patients with NET | Children or adolescents (under the age of 18 years) |
| Patients with liver metastases | ||
| Test of interest | SPECTa | |
| SPECT/CTb | ||
| SRSc | ||
| 123I-MIBG-Scintigraphyd | ||
| 18F-FDA-PETe | ||
| 18F-FDG-PETf | ||
| 18F-DOPA PET/CTg | ||
| PET/CTh | ||
| PET/MRIi | ||
| 111In-SRSj | ||
| 123I-SRSk | ||
| Study design | Randomized controlled trials (RCTs) | Case reports |
| Prospective and retrospective comparative cohort studies | ||
| Noncomparative cohort studies | ||
| Case-control studies | ||
| Case series | Reviews | |
| Reporting |
|
Studies that do not report the diagnostic accuracy |
| Studies that do not report the assessment of resectability |
aSingle photon emission computed tomography
bHybrid method of single photon emission computed tomography and computed tomography
cSomatostatin receptor scintigraphy
d(123) Iodine-metaiodobenzylguanidine scintigraphy
e(18) Fluoro-dopamine positron emission tomography
f(18) Fluoro-2-deoxy-D-glucose positron emission tomography
g (18) Fluoro-L-dihydroxyphenylalanine positron emission tomography
hHybrid method of positron emission tomography and computed tomography
i Hybrid method of positron emission tomography and magnetic resonance imaging
j(111) Indium-somatostatin receptor scintigraphy
k(123) Iodine-somatostatin receptor scintigraphy